Department of Hematology, Zhujiang Hospital, Southern Medical University, No. 253 GongyeDadaoZhong, Guangzhou, Guangdong, 510282, People's Republic of China.
J Exp Clin Cancer Res. 2018 Jan 22;37(1):12. doi: 10.1186/s13046-018-0682-x.
Oncogenic roles of epidermal growth factor receptor pathway substrate no.8 (EPS8) have been widely reported in various tumors, making targeting of EPS8 an appealing prospect. Here, we describe the role of EPS8 in acute myeloid leukemia (AML) and consider the potential of EPS8 as an anti-AML target. Nuclear localization signal (NLS) residues of tumor-associated proteins are crucial for cell cycle progression, and specific inhibitors derived from the NLS have inhibitory effect on cancer cells. The NLS in EPS8 has potential as a specific anti-AML target.
Gene Expression Omnibus expression profiles of AML patients were used to test associations between EPS8 expression and AML patient outcome. The biological characteristics of AML cells after EPS8 knockdown were analyzed in vitro and in vivo. A specific peptide (CP-EPS8-NLS) derived from the NLS of EPS8 (amino acids 298-310) was synthesized, and the anti-AML effects of CP-EPS8-NLS were analyzed in cancer cells and in xenograft models. Mutated CP-EPS8-NLS and penetratin served as controls.
We observed that elevated EPS8 expression in AML patients is associated with poor outcome. Knockdown of EPS8 significantly suppressed the survival of AML cells in vitro and in vivo. CP-EPS8-NLS interfered with EPS8-associated signaling and consequently exerted anti-AML activity. Importantly, CP-EPS8-NLS displayed anti-AML activity in various AML cell types, with diminished activity in PBMCs. CP-ESP8-NLS suppressed U937 cell proliferation, and injection of CP-EPS8-NLS exerted potent antitumor activity in the xenograft tumor models. A synergistic effect of CP-EPS8-NLS and chemotherapeutic agents was also observed in vitro and in vivo. Mechanistically, treatment of various AML cells with CP-EPS8-NLS downregulated the expression of EPS8 and its downstream pathways.
The function of CP-EPS8-NLS is explained by the presence of a NLS in EPS8, which has been shown to induce nuclear translocation, consequently resulting in EPS8 overexpression. These results indicate that EPS8 is a potential target for AML treatment.
表皮生长因子受体途径底物 8(EPS8)的致癌作用已在各种肿瘤中广泛报道,使针对 EPS8 成为一个有吸引力的前景。在这里,我们描述了 EPS8 在急性髓系白血病(AML)中的作用,并考虑了将 EPS8 作为抗 AML 靶点的潜力。肿瘤相关蛋白的核定位信号(NLS)残基对于细胞周期进展至关重要,并且源自 NLS 的特异性抑制剂对癌细胞具有抑制作用。EPS8 中的 NLS 具有成为特定抗 AML 靶点的潜力。
使用 AML 患者的基因表达综合组学表达谱来测试 EPS8 表达与 AML 患者结局之间的关联。在体外和体内分析 EPS8 敲低后 AML 细胞的生物学特性。合成了源自 EPS8(氨基酸 298-310)NLS 的特异性肽(CP-EPS8-NLS),并在癌细胞和异种移植模型中分析了 CP-EPS8-NLS 的抗 AML 作用。突变的 CP-EPS8-NLS 和 penetratin 用作对照。
我们观察到 AML 患者中 EPS8 表达升高与不良预后相关。EPS8 敲低显著抑制了 AML 细胞在体外和体内的存活。CP-EPS8-NLS 干扰了与 EPS8 相关的信号转导,从而发挥了抗 AML 活性。重要的是,CP-EPS8-NLS 在各种 AML 细胞类型中均具有抗 AML 活性,而在 PBMC 中活性降低。CP-ESP8-NLS 抑制 U937 细胞增殖,并且 CP-EPS8-NLS 注射在异种移植肿瘤模型中发挥了强大的抗肿瘤活性。CP-EPS8-NLS 与化疗药物的协同作用也在体外和体内观察到。在机制上,用 CP-EPS8-NLS 处理各种 AML 细胞会下调 EPS8 及其下游途径的表达。
CP-EPS8-NLS 的功能解释为 EPS8 中存在 NLS,该 NLS 已被证明可诱导核易位,从而导致 EPS8 过表达。这些结果表明 EPS8 是 AML 治疗的潜在靶点。